Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Hodel, Eva Maria ^a   Kay, Katherine ^a   Hayes, Daniel J ^a   Terlouw, Dianne J ^a,b   Hastings, Ian M ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

Author keywords

Anti malarials; Artemisinins; Dosing regimen; Drug resistance; Falciparum malaria; Lumefantrine; Mathematical model; Medication adherence; Patient adherence; Pharmacokinetics; Piperaquine

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE;

AFRICA; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; ASIA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; FOLLOW UP; MALARIA; MATHEMATICAL MODEL; MEDICATION COMPLIANCE; MONOTHERAPY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOKINETICS; SOUTH AND CENTRAL AMERICA; TREATMENT OUTCOME;

EID: 84901690856     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1475-2875-13-138     Document Type: Article

References (59)

1. World Health Organization, Technical Consultation On The Use Of Pharmacokinetic Analyses For Paediatric Medicine Development Geneva, Switzerland: World Health Organization 2009 http://www.who.int/childmedicines/ progress/Pharmacokinetic-June2009.pdf
2. A research agenda to underpin malaria eradication. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M, PLoS Med 2011 8 1000406 10.1371/journal.pmed.1000406 21311579
3. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. Kay K, Hastings IM, PLoS Comput Biol 2013 9 1003151 10.1371/journal.pcbi.1003151 23874190
4. Epidemiology of drug resistance in malaria. Wernsdorfer WH, Acta Trop 1994 56 143 156 10.1016/0001-706X(94)90060-4 8203301 (Pubitemid 24095228)
5. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. Austin DJ, White NJ, Anderson RM, J Theor Biol 1998 194 313 339 10.1006/jtbi.1997.0438 9778442 (Pubitemid 28479060)
6. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H, Parasitology 2000 121 Pt 3 237 246 11085244
7. Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Hoshen MB, Stein WD, Ginsburg H, Parasitology 1998 116 Pt 5 407 416 9614323 (Pubitemid 28221660)
8. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Hoshen MB, Stein WD, Ginsburg H, Parasitology 2002 124 9 15 11811806 (Pubitemid 34816180)
9. Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine. Hoshen MB, Stein WD, Ginsburg HD, Parasitology 2001 123 337 346 11676365 (Pubitemid 32937924)
10. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh N, Chotivanich K, Nosten F, Day NP, Socheat D, White NJ, Dondorp AM, White LJ, Proc Natl Acad Sci U S A 2011 108 397 402 10.1073/pnas.1006113108 21173254
11. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ, Antimicrob Agents Chemother 2000 44 3414 3424 10.1128/AAC.44.12.3414- 3424.2000 11083649 (Pubitemid 33009503)
12. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, Gamo-Benito J, McCaw J, Jamsen KM, Smith K, Simpson JA, Malar J 2012 11 303 10.1186/1475-2875-11-303 22931058
13. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Winter K, Hastings IM, Antimicrob Agents Chemother 2011 55 3380 3392 10.1128/AAC.01712-10 21537019
14. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. Czock D, Keller F, J Pharmacokinet Pharmacodyn 2007 34 727 751 10.1007/s10928-007-9069-x 17906920 (Pubitemid 350165274)
15. Developing Age-Based Dosing Regimens For Antimalarials. Hayes DJ, Phd Thesis University of Liverpool 2011
16. R: A language and environment for statistical computing. R Core Team, Vienna, Austria: R Foundation for Statistical Computing 2013 http://www.R-project.org/
17. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Hietala SF, Martensson A, Ngasala B, Dahlstrom S, Lindegardh N, Annerberg A, Premji Z, Farnert A, Gil P, Bjorkman A, Ashton M, Antimicrob Agents Chemother 2010 54 4780 4788 10.1128/AAC.00252-10 20713675
18. Pharmacokinetics of oral artemether in Thai patients with uncomplicated falciparum malaria. Karbwang J, Na-Bangchang K, Congpuong K, Thanavibul A, Wattanakoon Y, Molunto P, Fundam Clin Pharmacol 1998 12 242 244 10.1111/j.1472-8206.1998.tb00948.x 9565781 (Pubitemid 28154616)
19. Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Looareesuwan S, Wilairatana P, Viravan C, Vanijanonta S, Pitisuttithum P, Kyle DE, Am J Trop Med Hyg 1997 56 613 617 9230790 (Pubitemid 27318581)
20. Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Price R, van Vugt M, Nosten F, Luxemburger C, Brockman A, Phaipun L, Chongsuphajaisiddhi T, White N, Am J Trop Med Hyg 1998 59 883 888 9886194 (Pubitemid 29028916)
21. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwvan S, Am J Trop Med Hyg 1999 60 936 942 10403324 (Pubitemid 29296218)
22. Pharmacokinetic interactions of antimalarial agents. Giao PT, de Vries PJ, Clin Pharmacokinet 2001 40 343 373 10.2165/00003088-200140050-00003 11432537 (Pubitemid 32565596)
23. Clinical efficacy of high dose monotherapy of oral dihydroartemisinin in uncomplicated falciparum malaria in viet nam. Diem Thuy le T, Na-Bangchang K, Hung le N, Chong MT, Van Thang N, Van Binh N, Danh PT, Jpn J Infect Dis 2007 60 161 166 17642523 (Pubitemid 47365031)
24. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, Khanthavong M, Pongvongsa T, Ruangveerayuth R, Uthaisil C, Ubben D, Duparc S, Bacchieri A, Corsi M, Rao BHK, Bhattacharya PC, Dubhashi N, Ghosh SK, Dev V, Kumar A, Pukittayakamee S, PLoS One 2010 5 11880 10.1371/journal.pone.0011880 20689583
25. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D, Br J Clin Pharmacol 2004 57 253 262 14998421 (Pubitemid 38296988)
26. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, Lin E, Lammey J, Batty KT, Davis TM, Antimicrob Agents Chemother 2008 52 237 243 10.1128/AAC.00555-07 17967917
27. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NP, McGready R, Ashton M, Nosten F, White NJ, Antimicrob Agents Chemother 2008 52 1052 1061 10.1128/AAC.00955-07 18180343 (Pubitemid 351358388)
28. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NP, White NJ, Nosten F, Ouedraogo JB, Lindegardh N, Clin Pharmacol Ther 2012 91 497 505 10.1038/clpt.2011.254 22258469
29. Estimating regional centile curves from mixed data sources and countries. van Buuren S, Hayes DJ, Stasinopoulos DM, Rigby RA, ter Kuile FO, Terlouw DJ, Stat Med 2009 28 2891 2911 10.1002/sim.3667 19691045
30. World Health Organization, Guidelines For The Treatment Of Malaria Geneva: World Health Organization 2 2010
31. Eurartesim summary of product characteristics. European Medicines Agency, 2011 [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/001199/human-med-001450.jsp&mid=WC0b01ac058001d124 ]
32. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, 2003 WHO/HTM/RBM/2003.50
33. WHO, Global Antimalarial Drug Policy Database-Who African Region 2012 http://www.who.int/malaria/am-drug-policies-by-region-afro/en/index.html
34. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, Nambozi M, Valea I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D'Alessandro U, PLoS One 2009 4 7871 10.1371/journal.pone.0007871 19936217
35. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, PLoS Clin Trials 2007 2 20 10.1371/journal.pctr. 0020020 17525792 (Pubitemid 46860146)
36. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H, PLoS One 2008 3 2390 10.1371/journal.pone.0002390 18545692
37. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, D'Alessandro U, Trans R Soc Trop Med Hyg 2006 100 1105 1111 10.1016/j.trstmh.2006.01.001 16766006 (Pubitemid 44464010)
38. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, Ouedraogo JB, Clin Infect Dis 2007 45 1453 1461 10.1086/522985 17990228 (Pubitemid 351411875)
39. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. WorldWide Antimalarial Resistance Network DPSG, PLoS Med 2013 10 1001564 10.1371/journal.pmed.1001564 24311989
40. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, Genton B, Malar J 2010 9 48 10.1186/1475-2875-9-48 20149235
41. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP, Am J Trop Med Hyg 2004 71 525 530 15569777 (Pubitemid 39601144)
42. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Rahman MM, Dondorp AM, Day NPJ, Lindegardh N, Imwong M, Faiz MA, Bangali AM, Kamal ATMM, Karim J, Kaewkungwal J, Singhasivanon P, Trans R Soc Trop Med Hyg 2008 102 861 867 10.1016/j.trstmh.2008.05.022 18606428
43. Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. Simba DO, Kakoko D, Tomson G, Premji Z, Petzold M, Mahindi M, Gustafsson LL, Trans R Soc Trop Med Hyg 2012 106 3 9 10.1016/j.trstmh.2011.09.006 22099005
44. Antimalarial drug policy: making systematic change. Kitua AY, Lancet 1999 354 Suppl IV32 10691444
45. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ, Antimicrob Agents Chemother 2000 44 697 704 10.1128/AAC.44.3.697-704.2000 10681341 (Pubitemid 30117964)
46. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F, PLoS One 2009 4 6358 10.1371/journal.pone.0006358 19649267
47. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D, PLoS One 2014 9 84555 10.1371/journal.pone.0084555 24465418
48. Adherence and effectiveness of drug combination in curative treatment among children suffering uncomplicated malaria in rural Senegal. Souares A, Lalou R, Sene I, Sow D, Le Hesran JY, Trans R Soc Trop Med Hyg 2008 102 751 758 10.1016/j.trstmh.2008.05.016 18603111 (Pubitemid 351907775)
49. A qualitative study of the feasibility and community perception on the effectiveness of artemether-lumefantrine use in the context of home management of malaria in south-west Nigeria. Ajayi IO, Falade CO, Olley BO, Yusuf B, Gbotosho S, Iyiola T, Olaniyan O, Happi C, Munguti K, Pagnoni F, BMC Health Serv Res 2008 8 119 10.1186/1472-6963-8-119 18513447
50. Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Beer N, Ali AS, Rotllant G, Abass AK, Omari RS, Al-mafazy A-wH, Björkman A, Källander K, Tropical Med Int Health 2009 14 766 774 10.1111/j.1365-3156.2009.02289.x
51. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Depoortere E, Guthmann J-P, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, Legros D, Tropical Med Int Health 2004 9 62 67 10.1046/j.1365-3156.2003.01157.x (Pubitemid 38178013)
52. Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia. Lemma H, Lofgren C, San Sebastian M, Malar J 2011 10 349 10.1186/1475-2875-10- 349 22141751
53. Treatment with coartem (artemether-lumefantrine) in Papua New Guinea. Schoepflin S, Lin E, Kiniboro B, DaRe JT, Mehlotra RK, Zimmerman PA, Mueller I, Felger I, Am J Trop Med Hyg 2010 82 529 534 10.4269/ajtmh.2010.09-0334 20348494
54. Analysing malaria drug trials on a per-individual or per-clone basis: a comparison of methods. Jaki T, Parry A, Winter K, Hastings I, Stat Med 2013 32 3020 3038 10.1002/sim.5706 23258694
55. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Bindschedler M, Lefevre G, Degen P, Sioufi A, Am J Trop Med Hyg 2002 66 293 298 12139223 (Pubitemid 34756099)
56. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Luzzatto L, Seneca E, Br J Haematol 2014 164 469 480 10.1111/bjh.12665 24372186
57. Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. Onyeji CO, Ogunbona FA, Eur J Pharm Sci 2001 13 195 201 10.1016/S0928-0987(01)00108-7 11297904 (Pubitemid 32293539)
58. Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. Jamsen K, Duffull S, Tarning J, Lindegardh N, White N, Simpson J, Malar J 2012 11 143 10.1186/1475-2875-11-143 22551019
59. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Talisuna A, Staedke S, D'Alessandro U, Malar J 2006 5 50 10.1186/1475-2875-5-50 16780575 (Pubitemid 44141482)